ID | 1221 |
Name of the vaccine | ETEC expressing CFA/I and CFA/II |
Microbe | Bacteria |
Disease name | E.coli Infections |
Name of bacteria | Escherichia coli |
Type of vaccine | Inactivated |
Nucleic acid content | Circular duplex DNA |
Age | NA |
Description of the vaccine | Formalin-killed ETEC bacteria expressing CFA/I and CFA/II. |
Name of the manufacturer | NA |
Name of the manufacturing country | NA |
Year of manufacture | NA |
Clinical Phase status | Clinical |
Bacterial strain | Gram-negative, rod-shaped bacteria. |
Efficacy | 90% developed CFA-specific ASC responses after vaccination. |
Vaccine formulation | NA |
Dosage | Three doses, gap of 2 weeks. |
Mechanism of action | IgA-ASCs and moderate CFA/I- and CFA/II-specific IgM-secreting ASC (IgM-ASC) responses. |
Route of administration | Oral |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | Cholera toxin B subunit |
Repurposing | NA |
Side effects of vaccine | Slight abdominal discomfort. |
Post vaccination | NA |
Dose type | Combination (3 doses) |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=286&keywords= |
Other name | NA |
Additional Links | NA
|